NO20023951D0 - Arylpiperaziner og arylpiperidiner og deres anvendelse som metalloproteinaseinhiberende midler - Google Patents

Arylpiperaziner og arylpiperidiner og deres anvendelse som metalloproteinaseinhiberende midler

Info

Publication number
NO20023951D0
NO20023951D0 NO20023951A NO20023951A NO20023951D0 NO 20023951 D0 NO20023951 D0 NO 20023951D0 NO 20023951 A NO20023951 A NO 20023951A NO 20023951 A NO20023951 A NO 20023951A NO 20023951 D0 NO20023951 D0 NO 20023951D0
Authority
NO
Norway
Prior art keywords
arylpiperidines
arylpiperazines
metalloproteinase inhibitors
metalloproteinase
inhibitors
Prior art date
Application number
NO20023951A
Other languages
English (en)
Other versions
NO20023951L (no
Inventor
Bernard Christophe Barlaam
Robert Ian Dowell
Nicholas John Newcombe
Howard Tucker
David Waterson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20023951D0 publication Critical patent/NO20023951D0/no
Publication of NO20023951L publication Critical patent/NO20023951L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
NO20023951A 2000-02-21 2002-08-20 Arylpiperaziner og arylpiperidiner og deres anvendelse som metalloproteinaseinhiberende midler NO20023951L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00400469 2000-02-21
PCT/GB2001/000616 WO2001062751A1 (en) 2000-02-21 2001-02-15 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents

Publications (2)

Publication Number Publication Date
NO20023951D0 true NO20023951D0 (no) 2002-08-20
NO20023951L NO20023951L (no) 2002-08-20

Family

ID=8173566

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20023951A NO20023951L (no) 2000-02-21 2002-08-20 Arylpiperaziner og arylpiperidiner og deres anvendelse som metalloproteinaseinhiberende midler

Country Status (13)

Country Link
US (1) US20030139419A1 (no)
EP (1) EP1261595A1 (no)
JP (1) JP2003524008A (no)
KR (1) KR20020079882A (no)
CN (1) CN1404474A (no)
AU (1) AU3385401A (no)
BR (1) BR0108500A (no)
CA (1) CA2396971A1 (no)
IL (1) IL150882A0 (no)
MX (1) MXPA02008112A (no)
NO (1) NO20023951L (no)
WO (1) WO2001062751A1 (no)
ZA (1) ZA200205845B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119472D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
GB0119473D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Compounds
GB0119474D0 (en) 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
NZ536116A (en) 2002-04-03 2007-01-26 Topotarget Uk Ltd Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors
TW200410923A (en) * 2002-10-17 2004-07-01 Ono Pharmaceutical Co Therapeutic agent for chronic obstructive pulmonary disease
CA2513246A1 (en) 2003-01-17 2004-08-05 Topotarget Uk Limited Carbamic acid compounds comprising an ester or ketone linkage as hdac inhibitors
EP1602655A4 (en) 2003-03-07 2010-06-09 Kowa Co BENZOFURAN DERIVATIVE
JP2006527754A (ja) * 2003-06-19 2006-12-07 セルテック アール アンド ディ リミテッド Ｃｄ２３分断阻害物質としてのヒドロキサム酸スルホンアミド
US20060241118A1 (en) * 2004-06-18 2006-10-26 Celltech R&D Limited Hydroxamate sulfonamides as cd23 shedding inhibitors
KR100838645B1 (ko) * 2006-09-28 2008-06-16 한국화학연구원 베타-세크리테아제 활성을 억제하는 피페리딘 화합물
US20210393632A1 (en) 2018-10-04 2021-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0968182B1 (en) * 1996-08-07 2004-05-06 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
WO1998016514A1 (en) * 1996-10-16 1998-04-23 American Cyanamid Company Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
GB9725782D0 (en) * 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
WO2000012477A1 (en) * 1998-08-29 2000-03-09 British Biotech Pharmaceuticals Limited Hydroxamic acid derivatives as proteinase inhibitors
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds

Also Published As

Publication number Publication date
CN1404474A (zh) 2003-03-19
NO20023951L (no) 2002-08-20
US20030139419A1 (en) 2003-07-24
MXPA02008112A (es) 2002-11-29
EP1261595A1 (en) 2002-12-04
AU3385401A (en) 2001-09-03
WO2001062751A1 (en) 2001-08-30
JP2003524008A (ja) 2003-08-12
IL150882A0 (en) 2003-02-12
CA2396971A1 (en) 2001-08-30
KR20020079882A (ko) 2002-10-19
BR0108500A (pt) 2003-04-29
ZA200205845B (en) 2003-10-22

Similar Documents

Publication Publication Date Title
NO20026010D0 (no) Substituerte quinazolinderivater og deres anvendelse som inhibitorer
DK1133477T3 (da) Substituerede benzimidazoler og deres anvendelse som parpinhibitorer
DK1347955T3 (da) Nye mandelsyrederivater og deres anvendelse som throbin-hæmmere
NO991922L (no) Heteroarylsuccinamider og deres anvendelse som metalloproteinaseinhibitorer
CY2015053I1 (el) Υδροξαμικα παραγωγα χρησιμα ως αναστολεις δεακετυλασης
DK1498413T3 (da) 4-aminopicolinater og deres anvendelse som herbicider
NO20025357L (no) Antranylamider og deres anvendelse som legemidler
NO20042719L (no) Substituerte 2-amino-cykloalkankarboksamider og deres anvendelse som protease-inhibitorer
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
NO992492D0 (no) Benzamidoaldehyder og deres anvendelse som cystein-protease-inhibitorer
DK0989121T3 (da) Substituerede benzamider og deres anvendelse som immunmodulatorer
NO20032490L (no) Substituerte 2-anilin-benzimidazoler og deres anvendelse som NHE-inhibitorer
NO20025150L (no) 2-acylindolderivater og deres anvendelse som antitumormidler
NO20034995D0 (no) Aromatiske sulfonhydroksymater og deres anvendelse som proteaseinhibitorer
DK1150996T3 (da) Nye amidinobenzylaminderivater og deres anvendelse som thrombin-inhibitorer
NO20013853D0 (no) Heteroarylamidiner, metylamidiner og guanidiner som proteaseinhibitorer
NO20023951D0 (no) Arylpiperaziner og arylpiperidiner og deres anvendelse som metalloproteinaseinhiberende midler
NO20025504L (no) Nye tiokromanderivater og anvendelse derav som trombininhibitorer
NO20030243D0 (no) Nye forbindelser og deres anvendelse som glysintransportinhibitorer
DK1214302T3 (da) Substituerede 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-oner og deres anvendelse som lipasehæmmere
NO20026164L (no) Benzoksazepinoner og deres anvendelse som squalen syntase inhibitorer
NO20030813L (no) Bifenylderivater og deres anvendelse som integrininhibitorer
NO20025884L (no) 2-aminotiazolinderivater og deres anvendelse som NO- syntaseinhibitorer
DK1367055T3 (da) Isoquinolinylcarboxamider og deres anvendelse som krampestillende midler
NO20030812L (no) Bifenylderivater og anvendelse derav som integrininhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application